Related Experiment Videos
[Serum concentration of gentamicin in newborn infants]
B Töpke1, W Buchenau, U Karstädt
1Klinik und Poliklinik für Kindermedizin, Medizinischen Akademie Erfurt.
Insights
Gentamicin therapy in premature infants often leads to subtherapeutic or toxic serum levels, especially in lower birth weight neonates. Adjusting initial doses and monitoring levels are crucial for safe and effective treatment.
Area of Science:
- Neonatal Pharmacology
- Antibiotic Pharmacokinetics
- Pediatric Infectious Diseases
Context:
- Premature infants often require antibiotic treatment for infections.
- Gentamicin is a commonly used antibiotic in neonates.
- Establishing optimal dosing regimens in premature infants is challenging due to immature organ function.
Purpose:
- To determine serum gentamicin levels in premature infants receiving standard intramuscular doses.
- To evaluate the safety and efficacy of current gentamicin dosing protocols in this population.
- To identify factors influencing gentamicin pharmacokinetics in preterm neonates.
Summary:
- Serum gentamicin levels were measured in 15 premature infants (birth weight 1,120-2,250 g, gestational age 27-36 weeks) using intramuscular doses of 6 mg/kg/day every 12 hours.
- Gentamicin levels increased during the first 72 hours; by day 2, 46.5% of infants had subtherapeutic levels, and over 60% experienced toxic levels during steady state.
- Higher levels were observed in infants weighing less than 1,500 g, indicating weight-based pharmacokinetic differences.
Impact:
- Findings suggest current gentamicin dosing may lead to suboptimal therapeutic drug monitoring in premature infants.
- Recommendations include doubling the initial dose and adjusting subsequent doses or intervals based on therapeutic drug monitoring.
- Optimized gentamicin dosing strategies are needed to improve treatment outcomes and minimize toxicity in neonates.
Abstract:
Serum levels of gentamicin were determined in 15 premature infants (birth weight 1,120-2,250 g, gestational age 27-36 weeks) by agar immunoassay. The intramuscular applied doses was 6 mg/kg/day, the doses interval 12 hours. We found an increase of the gentamicin serum level during the first 72 hours after the beginning of therapy. At the second day of treatment the serum levels in 46.5% of all patients were determined below the therapeutic concentration, but a toxic level was found in more than 60% of all cases during the period of steady state. The serum levels were higher in preterm newborns of less than 1,500 g birth weight, then in more mature infants. We recommend: 1. To double the first doses of gentamicin 2. To modify the gentamicin level by expanded intervals of therapy and/or reduced doses under monitoring, especially during the first week of life.